Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma

被引:137
作者
Murakami, Shuji [1 ]
Ito, Hiroyuki [1 ]
Tsubokawa, Norifumi [3 ]
Mimae, Takahiro [3 ]
Sasada, Shinsuke [3 ]
Yoshiya, Tomoharu [3 ]
Miyata, Yoshihiro [3 ]
Yokose, Tomoyuki [2 ]
Okada, Morihito [3 ]
Nakayama, Haruhiko [1 ]
机构
[1] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa 2418515, Japan
[2] Kanagawa Canc Ctr, Dept Pathol, Yokohama, Kanagawa 2418515, Japan
[3] Hiroshima Univ, Dept Surg Oncol, Hiroshima, Japan
关键词
Lung adenocarcinoma; Predominant subtype; Clinical stage IA; TUMOR SIZE; INTERNATIONAL ASSOCIATION; PERIPHERAL ADENOCARCINOMA; LOCAL RECURRENCE; CANCER; SURVIVAL; GEFITINIB; MUTATIONS; REVISION; EDITION;
D O I
10.1016/j.lungcan.2015.06.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objectives: We analyzed and validated the prognostic utility of the new International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) for clinical stage IA lung adenocarcinoma (ADC) classification of adenocarcinoma (ADC). Methods: We retrospectively reviewed 347 patients with clinical stage IA nonmucinous ADC, who had undergone complete resection. The histological subtype was classified according to the predominant subtype, as proposed by the new IASLC/ATS/ERS ADC classification. Results: The histopathological subtypes, defined according to the new IASLC/ATS/ERS ADC classification, were ADC in situ (AIS) in 56 patients (16.1%), minimally invasive ADC (MIA) in 15 (4.3%), lepidicpredominant ADC in 109 (31.4%), papillary-predominant ADC in 70 (20.2%), acinar-predominant ADC in 61 (17.6%), solid-predominant ADC in 30 (8.6%), and micropapillary-predominant ADC in 6 (1.7%). The 5-year disease-free survival (DFS) rate was 100% for both AIS and MIA. All cases of recurrence involved invasive ADC. The 5-year DFS for lepidic-predominant ADC was 99.0%; acinar-predominant ADC, 82.4%; papillary-predominant ADC, 80.8%; solid-predominant ADC, 73.6%; and micropapillary-predominant ADC, 33.3%. The predominant subtype of ADC was significantly correlated with DFS (P < 0.0001). Multivariate analysis indicated that the pathological stage was an independent predictor of DFS (P = 0.031). Other independent predictors of increased risk of recurrence were the presence of vascular or lymphatic invasion (HR = 4.96, P = 0.001), and a pathological stage more advanced than IB (HR = 2.87, P = 0.010). The coincidence between the clinical stage and pathological stage was 79.8%. The stage migration was found in 53.3% of solid-predominat ADC and in 83.3% of micropapillary-predominant ADC. Conclusion: The new IASLC/ATSIERS ADC classification has prognostic value in predicting the recurrence and survival of patients with clinical stage IA ADC. The frequency of stage migration was found in more than half of solid and micropapillary predominant ADCs. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:199 / 204
页数:6
相关论文
共 23 条
[1]
Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease [J].
Gajra, A ;
Newman, N ;
Gamble, GP ;
Abraham, NZ ;
Kohman, LJ ;
Graziano, SL .
LUNG CANCER, 2003, 42 (01) :51-57
[2]
GEMMA A, 1991, ACTA PATHOL JAPON, V41, P737
[3]
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[4]
HARPOLE DH, 1995, CANCER RES, V55, P51
[5]
Molecular origins of cancer: Lung cancer [J].
Herbst, Roy S. ;
Heymach, John V. ;
Lippman, Scott M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1367-1380
[6]
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy [J].
Inoue, Akira ;
Kobayashi, Kunihiko ;
Usui, Kazuhiro ;
Maemondo, Makoto ;
Okinaga, Shoji ;
Mikami, Iwao ;
Ando, Masahiro ;
Yamazaki, Koichi ;
Saijo, Yasuo ;
Gemma, Akihiko ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Ikebuchi, Kenji ;
Nukiwa, Toshihiro ;
Morita, Satoshi ;
Hagiwara, Koichi .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1394-1400
[7]
Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients [J].
Kelsey, Chris R. ;
Marks, Lawrence B. ;
Hollis, Donna ;
Hubbs, Jessica L. ;
Ready, Neal E. ;
D'Amico, Thomas A. ;
Boyd, Jessamy A. .
CANCER, 2009, 115 (22) :5218-5227
[8]
Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients [J].
Liu Chao ;
Huang Yi-Sheng ;
Chen Yu ;
Yan Li-Xu ;
Luo Xin-lan ;
Luo Dong-Lan ;
Chen Jie ;
Wu Yi-Lon ;
Liu Yan Hui .
LUNG CANCER, 2014, 86 (02) :164-169
[9]
Maemondo M., 2015, NEW ENGL J MED, V362, P2380
[10]
INCIDENCE OF LOCAL RECURRENCE AND 2ND PRIMARY TUMORS IN RESECTED STAGE-I LUNG-CANCER [J].
MARTINI, N ;
BAINS, MS ;
BURT, ME ;
ZAKOWSKI, MF ;
MCCORMACK, P ;
RUSCH, VW ;
GINSBERG, RJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (01) :120-129